Logo

Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

Share this

Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

Shots:

  • The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone
  • Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage of participants achieving A1C <7%: 81.8%/84.5%/ 78.3% vs 23.0%; percentage of participants achieving A1C <5.7%: 30.9% /26.8%/38.4% vs 1.4% respectively
  • The highest dose led to A1C reduction of 2.07 % with a reduction in body weight by 9.5 kg (11 %)- 51.7 % of patients achieved an A1C less than 5.7 %

 Ref: PRNewswire | Image: Diario AS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions